
Glenmark Pharma shares advanced as much as 2.45% to hit an intraday high of ₹2,680 per unit on the NSE on Wednesday, after its subsidiary, Ichnos Glenmark Innovation, announced that it has submitted an Investigational New Drug (IND) application to the US FDA.
